Pharmacies receiving massive rebates from generic drug-makers

Silversides, Ann
August 2005
CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p342
Academic Journal
This article looks at several issues associated with the Ontario government's Transparent Drug System for Patients Act 2006. The legislation was aimed at generating savings in the Ontario Drug Benefit (ODB) program. The annual cost of the ODB program is disclosed. During committee hearings on Bill 102, it was revealed that pharmacies were receiving rebates from generic drug manufacturers. The salient features of Bill 102, which amends the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act, are listed.


Related Articles

  • Bright Prospects for Generic Market.  // Pharmaceutical Executive;Mar2006, Vol. 26 Issue 3, pS15 

    The article focuses on possible growth of the market for generic drugs in South Africa. The authors inform that generic medication is the only realistic means for the majority of South Africans affected with HIV/AIDS and TB access to affordable treatments. They describe that government...

  • PBM's "MAC" Mousetraps. Cahn, Linda J. // Benefits & Compensation Digest;Feb2009, Vol. 46 Issue 2, p24 

    The article suggests that clients of pharmaceutical benefit management (PBM) companies must understand how the concept of maximum allowable cost (MAC) in contract definitions, pricing formulas and generic guarantees can determine who retains the savings available from using generic drugs. It is...

  • Generic opportunities slow as more specialty drugs emerge. Meyer, Harris // Managed Healthcare Executive;Jan2010, Vol. 20 Issue 1, p7 

    The article presents studies on the emergence of specialty drugs against generic drugs in the U.S. in 2009. Actuary Troy Filipek believes that there will be less dispensing of genertic drugs after 2011 because fewer major brand-name drugs will go off patent. A study in an issue of "Health...

  • Sales explode as patents expire.  // Drug Store News;9/25/2006, Vol. 28 Issue 12, p24 

    The article reports on the expiration of patent licenses of various branded drugs which triggered the increase in sales of generic drugs in the U. S. by 21%. This trend is expected to continue since there are still branded drugs whose patent licenses are yet to expire and as the Food and Drug...

  • Product focus -- Generic drugs in Brazil.  // Market: Latin America;Jan2006, Vol. 14 Issue 1, p2 

    The article reports on the availability of generic drugs in Brazil. It is added that generic drugs are making healthcare more affordable for consumers in the country. An overview of the Brazilian generic drug market review posted on the Web site of Knowledge@Wharton on December 14, 2005 is provided.

  • Product focus--Generic drugs.  // Market: Latin America;Feb2007, Vol. 15 Issue 2, p2 

    The article reports on the performance of the pharmaceutical industry of Latin America and the contribution of generic drugs to the market. Mexico and Brazil have the biggest market share in pharmaceutical sales. Market growth was driven by the sales of generic drugs. Generic drugs are expected...

  • News in brief . . .  // PharmacoEconomics & Outcomes News;2/26/2005, Issue 472, p14 

    Presents news briefs on issues and events concerning pharmaceutical industries as of February 26, 2005. Increase in the sales of the etanercept drug of Wyeth Inc. in Sweden; Expectation on the competition between brandname and generic drugs in the U.S. by 2008; Percentage of the price reduction...

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;4/5/2008, Issue 550, p11 

    The article discusses the results of two studies in the drug industry in 2008. A study found that Canadians could save $Can750 million/year if generic drug use was increased to the U.S. level. Another study showed that Great Britain's pharmaceutical industry has little confidence in the market...

  • Ethical Pharma Companies Fight Generics Head On. Scott, Alex // Chemical Week;7/5/2006, Vol. 168 Issue 23, p22 

    This article reveals that some ethical pharmaceutical companies have started to challenge the established pricing model for branded pharmaceuticals that go off patent. Merck and Pfizer have each opted to offer major price discounts on leading drugs that recently went off patent, to fight...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics